Abstract 4CPS-249 Table 1
Ceftazidime–avibactamCeftolozane–tazobactam
Patients (n) 24 16
Demographic variables
Age (median (IQR)) (years) 68.5 (63.5–75) 67 (57.5–73.7)
Sex (men) (%) 58.3 56.2
Type of infection (%)
cUTIs 12.5 0
cIAIs 41.7 31.25
CAP and VABP 20.8 37.5
Bacteraemia 12.5 25
Other 12.5 6.25
Microorganisms isolated (%) 100 93.75
P aeruginosa multiresistant 20.8 68.7
K pneumoniae 70.8 0
E coli BLEE 4.2 12.5
Other 4.2 12.5
Duration of treatment (median (IQR)) (days) 11.5 (6.5–16.5) 12.5 (8–17.75)